Free Trial
NASDAQ:OCS

Oculis Q4 2023 Earnings Report

Oculis logo
$17.84 -0.10 (-0.53%)
As of 02:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.42
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.28 million
Beat/Miss
Missed by -$70.00 thousand
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 18, 2024
Conference Call Time
3:00AM ET

Upcoming Earnings

Oculis' Q2 2025 earnings is scheduled for Tuesday, August 26, 2025

Earnings Documents

Oculis Earnings Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat